Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury
Ischemic brain injury triggers neuronal cell death by apoptosis via caspase activation and by necroptosis through activation of the receptor-interacting protein kinases (RIPK) associated with the tumor necrosis factor-alpha (TNF-α)/death receptor. Recent evidence shows RIPK inhibitors are neuroprote...
Main Authors: | Shelly A Cruz, Zhaohong Qin, Alexandre F. R. Stewart, Hsiao-Huei Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
Series: | Neural Regeneration Research |
Subjects: | |
Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2018;volume=13;issue=2;spage=252;epage=256;aulast=Cruz |
Similar Items
-
Loss of IRF2BP2 in Microglia Increases Inflammation and Functional Deficits after Focal Ischemic Brain Injury
by: Shelly A. Cruz, et al.
Published: (2017-07-01) -
RIP3‐mediated necroptosis increases neuropathic pain via microglia activation: necrostatin‐1 has therapeutic potential
by: Ping Fang, et al.
Published: (2021-10-01) -
Targeting RIP Kinases in Chronic Inflammatory Disease
by: Mary Speir, et al.
Published: (2021-04-01) -
Triad3A displays a critical role in suppression of cerebral ischemic/reperfusion (I/R) injury by regulating necroptosis
by: Zhang Yuan, et al.
Published: (2020-08-01) -
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)